戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 nsistent with that of patients known to have metastatic colon cancer.
2 ithelial and tumor-initiating cells in human metastatic colon cancer.
3 rphisms as independent prognostic markers in metastatic colon cancer.
4 as prognostic marker in female patients with metastatic colon cancer.
5 Gb(3)), this molecule is highly expressed in metastatic colon cancer.
6 pression in cancer-associated fibroblasts in metastatic colon cancer.
7  ceramide analogues in inducing apoptosis in metastatic colon cancer.
8 s in duration was observed in a patient with metastatic colon cancer.
9 sion of 5-FU and leucovorin for treatment of metastatic colon cancer.
10 ncer, and liver metastasis in a patient with metastatic colon cancer.
11 ated in this manner a molecular karyotype of metastatic colon cancer.
12  with tumor destruction for the treatment of metastatic colon cancer.
13 nsurance, an uninsured man is diagnosed with metastatic colon cancer.
14 quently mutated or deleted in pancreatic and metastatic colon cancers.
15 inor response was observed in a patient with metastatic colon cancer (5 months) at the 480-mg/m(2)-do
16 s into the peripheral blood of patients with metastatic colon cancer and may be associated with incre
17 mbined with oxaliplatin may have efficacy in metastatic colon cancer and may provide the first indica
18                     RNA was extracted from a metastatic colon cancer and used to load autologous DCs.
19  is required for the survival of primary and metastatic colon cancers and that oncogenic K-RAS activa
20  may represent a novel approach for treating metastatic colon cancers by mitigating the development o
21  with MTX displayed significant synergy in a metastatic colon cancer cell line and was effective in a
22             Stable transfection of the SW620 metastatic colon cancer cell line with Drg-1 cDNA induce
23 gration of the MUC2 antisense construct into metastatic colon cancer cells (LS LiM6) resulted in an 8
24    Introduction of galectin 3 antisense into metastatic colon cancer cells (LSLiM6, HM7) resulted in
25                                We found that metastatic colon cancer cells are able to transfer their
26 ies revealed that overexpression of Drg-1 in metastatic colon cancer cells reduced in vitro invasion
27                                KM12L4A human metastatic colon cancer cells were stably transfected wi
28 blishment of APA profiles characteristic for metastatic colon cancer cells, by regulating poly(A) sit
29 ry to normal murine liver with a concomitant metastatic colon cancer challenge.
30                         Here, we report that metastatic colon cancer contains clonally derived tumor
31    Assessment of tissues from a patient with metastatic colon cancer demonstrated a more than threefo
32 broblast cell cultures were established from metastatic colon cancer in liver, liver away from the me
33 val in a preclinical organoid-based model of metastatic colon cancer in mice.
34 ithelial cells also expressed CD133, whereas metastatic colon cancers isolated from liver had distinc
35  use and allows noninvasive visualization of metastatic colon cancer lesions in multiple organs.
36 put flow cytometric profiling of primary and metastatic colon cancer lines (SW480, SW620, and HCT116)
37  (OS) in female, but not male, patients with metastatic colon cancer (log-rank test, P = .038).
38 ciated with sex-specific clinical outcome in metastatic colon cancer patients treated with FU-based c
39 f EGFR were analyzed in genomic DNA from 318 metastatic colon cancer patients, 177 males and 141 fema
40                         In an additional two metastatic colon cancer patients, we detected CD8(+) neo
41 stration of an Ad vector to individuals with metastatic colon cancer resulted in a robust antibody re
42                          Surgically resected metastatic colon cancer samples were evaluated for Fas A
43 s of active matriptase in 68% of primary and metastatic colon cancer sections from tissue microarrays
44                          Restoring oxygen in metastatic colon cancer through ITPP inhibits tumor spre
45                             One patient with metastatic colon cancer treated at the 500-mg bid dose h
46 ed 318 patients (177 men and 141 women) with metastatic colon cancer treated between 1992 and 2003 at
47  patients with metastatic prostate cancer or metastatic colon cancer were injected s.c. into nude mic